Platelet-rich plasma

Where the papers sit

11 papers from the last 6 months study platelet-rich plasma directly · updated from PubMed 2 Oct 2026

• Regenerative Tissue Repair

  Adjunctive regenerative treatment is being applied across ischemic ocular injury, chronic ulcers, infected bone defects, fat grafting and chronic migraine. Protocols and retrospective cohorts emphasize functional recovery, graft survival, wound closure and symptom relief. Lidocaine, debridement, ultrasound-guided injection and propensity-score matching recur as ways to refine delivery or evaluate benefit. Evidence remains indication-specific, with no single clinical application clearly dominant.

  6 papers · 54.5%

• Regenerative Biomaterial Therapy

  PRP is being paired with engineered materials to extend regenerative treatment beyond injection alone. Dopamine-based nanoparticles are used to scavenge reactive oxygen species in knee osteoarthritis, while hyaluronic acid provides a clinical comparator in obese patients. Chitosan and chitosan-silver nanoparticles are tested as wound-healing adjuncts in full-thickness skin injury. The work is moving toward disease-specific combinations, but clinical evidence remains less mature than the preclinical biomaterial studies.

  3 papers · 27.3%

• Stem Cell Biologic Development

  Stem-cell biologics are being linked to mechanistic repair of neural injury and to stronger standards for reporting biologic studies. PRP-primed mesenchymal stem-cell exosomes are examined for reducing neuronal apoptosis and autophagy while promoting nerve regeneration after spinal cord injury. PTEN and PIK3CB, alongside high-throughput sequencing, point toward pathway-level validation rather than empirical cell therapy alone. Minimum-information standards remain an open requirement for comparing these interventions.

  2 papers · 18.2%